{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:30:57Z","timestamp":1778657457441,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>HIV integrase strand transfer inhibitors (INSTI) are considered well tolerated with few treatment-limiting adverse effects. However, emerging data from clinical trials has identified excessive weight gain possibly due to INSTI alone or with tenofovir alafenamide as a new and possible long-term complication of combination antiretroviral therapy (cART). Identifying who is at greatest risk and whether the unintended weight gain is reversible remain unanswered questions. We report a return to baseline weight after switching back to tenofovir disoproxil\/emtricitabine\/efavirenz (Atripla\u00ae) in a woman who had profound weight gain due to tenofovir alafenamide\/emtricitabine\/cobicistat\/elvitegravir (Genvoya\u00ae).<\/jats:p>","DOI":"10.1177\/0956462420964341","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T01:32:39Z","timestamp":1605144759000},"page":"92-95","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide discontinuation and return to normal weight"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-8677","authenticated-orcid":false,"given":"Blake","family":"Max","sequence":"first","affiliation":[{"name":"Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County Health, Chicago, IL, USA"},{"name":"Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"DeMarais","sequence":"additional","affiliation":[{"name":"Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County Health, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"bibr1-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ192"},{"key":"bibr2-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"bibr3-0956462420964341","volume-title":"Clin Infect Dis","author":"Sax PE"},{"key":"bibr4-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz414"},{"key":"bibr5-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"bibr6-0956462420964341","doi-asserted-by":"crossref","unstructured":"Kouanfack C, Mpoudi-Etame M, Bassega PO, et\u00a0al. NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low -dose efavirenz-based regimen for the treatment of HIV-1.\n                      N Eng J Med\n                      2019; 381(9): 816\u2013826.","DOI":"10.1056\/NEJMoa1904340"},{"key":"bibr7-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"key":"bibr8-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"bibr9-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912240-00002"},{"key":"bibr10-0956462420964341","author":"Moyle G","year":"2010","journal-title":"AIDS Rev"},{"key":"bibr11-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1086\/340863"},{"key":"bibr12-0956462420964341","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (accessed 17 June 2020)."},{"key":"bibr13-0956462420964341","unstructured":"European AIDS clinical society-guidelines\n                      . Version 10.0, https:\/\/eacs.sanfordguide.com\/ (accessed 17 June 2020)."},{"key":"bibr14-0956462420964341","unstructured":"Mallon P, et\u00a0al. Weight gain before and after switch from TDF to TAF. In:\n                      23rd International AIDS conference\n                      , 6\u201310 July 2020 (abstract 3283)."},{"key":"bibr15-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.12.029"},{"key":"bibr16-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001495"},{"key":"bibr17-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30277-6"},{"key":"bibr18-0956462420964341","doi-asserted-by":"crossref","unstructured":"Gorwood J, Bourgeois C, Pourcher V, et\u00a0al. The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes.\n                      Clin Infect Dis.\n                      Epub ahead of print 13 March 2020. DOI: 10.1093\/cid\/ciaa259.","DOI":"10.1093\/cid\/ciaa259"},{"key":"bibr19-0956462420964341","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00483-5"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420964341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462420964341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462420964341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:41:22Z","timestamp":1777675282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462420964341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/0956462420964341"],"URL":"https:\/\/doi.org\/10.1177\/0956462420964341","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]}}}